Background: This study investigated the differences of the clinical treatment effect, prognosis, and immune functions of patients with aneurysmal subarachnoid hemorrhage (aSAH) between the treatment of intracranial clipping and interventional embolization. Methods: A total of 120 aSAH patients were recruited for this study. Participants were randomly allocated into the interventional embolization group (n = 60) and the intracranial clipping group (n = 60). The prognosis of patients was examined by Glasgow Outcome Scale (GOS). Serum immunoglobulin (Ig)G, IgA, and IgM levels were evaluated by immunoturbidometric method. The serum levels of C-reactive protein (CRP), cortisol (Cor), and interleukin-6 (IL-6) were quantified using enzyme-linked imResults: The rate of patients with a good prognosis was 28.3% in the interventional embolization group when compared to 18.3% in the intracranial clipping group. After treatment, the interventional embolization group had lower incidence of complications (p = 0.0006), longer hospital duration (p = 0.0032), and higher costs (p < 0.0001) than the intracranial clipping group. Meanwhile, serum levels of IL-6, cortisol, and CRP of the interventional embolization group were significantly lower than those in the intracranial clipping group 1-day and 3-day post-operation (allp < 0.05). Conclusions: In conclusion, aSAH patients treated with interventional embolization had a lower incidence of complications, better prognosis, shorter hospital duration, and lower degree of stress response and immunosuppression than those treated with intracranial clipping.